Pfizer has upgraded the bottom-end of its full-year (FY) revenue outlook by $500m as performance from the drugmaker's lead products more than compensated for weaker Covid-19-related sales.
Pfizer now expects 2026 revenue to land between $60.5bn and $62.5bn, up from the $59.5bn to $62.5bn range it previously forecast.
According to the big pharma company, the revised outlook reflects a $1.5bn better-than-expected performance from its non-Covid products. Sales for Covid-19 products, which include antiviral Paxlovid and mRNA vaccine Comirnaty, are conversely expected to bring in $1bn less. The former's sales were down 95% in Q2, while the latter dropped 34%.
Pfizer emerged as a pharmaceutical powerhouse during the pandemic, but lower infection rates and narrower use cases mean its Covid-19 brands are impacting the company's bottom line.
Pfizer still recorded revenues of $15bn in Q2, up 3% from the same quarter in 2025, meaning its non-Covid products more than offset headwinds. This figure beat consensus estimates, as per Citi ******* ysts.
#covid #sales #bottom #performance
Pfizer now expects 2026 revenue to land between $60.5bn and $62.5bn, up from the $59.5bn to $62.5bn range it previously forecast.
According to the big pharma company, the revised outlook reflects a $1.5bn better-than-expected performance from its non-Covid products. Sales for Covid-19 products, which include antiviral Paxlovid and mRNA vaccine Comirnaty, are conversely expected to bring in $1bn less. The former's sales were down 95% in Q2, while the latter dropped 34%.
Pfizer emerged as a pharmaceutical powerhouse during the pandemic, but lower infection rates and narrower use cases mean its Covid-19 brands are impacting the company's bottom line.
Pfizer still recorded revenues of $15bn in Q2, up 3% from the same quarter in 2025, meaning its non-Covid products more than offset headwinds. This figure beat consensus estimates, as per Citi ******* ysts.
#covid #sales #bottom #performance
2 months ago
